Nanoparticle Dactinomycin for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a long-felt need for effective treatments for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), including NPM1-mutated AML, as current therapies are inadequate in addressing these conditions.
Innovation Solution
A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, specifically designed with polymers such as PLA-mPEG or PLGA-mPEG, with controlled size and molecular weight, is administered to treat MDS and AML, potentially combined with additional chemotherapeutic drugs to enhance efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dactinomycin is administered conventionally, then it can treat MDS and AML, but it causes severe side effects and has limited efficacy
Solution Approach 1:
The patent uses nanoparticles as an intermediary carrier to deliver dactinomycin to target cells. The nanoparticle structure (comprising a polymer core and shell) mediates between the drug and biological system, enabling controlled release and reduced toxicity while maintaining or enhancing therapeutic efficacy against MDS and AML
Solution Approach 2:
The patent modifies the physical and chemical parameters of dactinomycin by encapsulating it in nanoparticles with specific characteristics (size: 50-200 nm, polymer composition, drug-to-polymer ratio). These parameter changes alter the drug's pharmacokinetic and pharmacodynamic properties, improving efficacy and reducing side effects
2Reliability
If dactinomycin is encapsulated in nanoparticles with specific size and composition, then treatment efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the drug delivery system into distinct functional components: a polymer core (PLA, PLGA, or PCL) for drug encapsulation and a shell layer (PEG or PEG-lipid) for stability and stealth properties. This segmentation allows independent optimization of each component while simplifying the overall formulation process
Solution Approach 2:
The patent employs composite nanoparticle structures combining different biocompatible materials (polymers and PEG derivatives) with complementary properties. The composite structure leverages the advantages of each material (biodegradability of PLA/PLGA/PCL, stealth properties of PEG) to achieve enhanced therapeutic performance
Data Source
AI summary
The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.